Sunil Healthcare
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Sunil Healthcare received revised ratings from Brickwork Ratings India for its bank facilities effective 3 October 2026. The long-term facilities were rated BWR BBB- with a stable outlook, up from CARE BB+ with a stable outlook, while short-term facilities were rated BWR A3, up from CARE A4+. The company manufactured empty hard gelatin and HPMC capsule shells at its Alwar plant in Rajasthan with installed capacity of about 15 billion capsules a year. Consolidated revenue was about Rs 87.7 crore in the year to March 2026, with exports accounting for 39% of sales and one customer contributing more than 10% of revenue. Its bank ratings had stepped down from BBB in FY23 to BB+ by FY26, while total borrowings stood at Rs 55.78 crore against cash of Rs 7.4 lakh.
Powered by Tijori
Sunil Healthcare received revised ratings from Brickwork Ratings India for its bank facilities effective 3 October 2026. The long-term facilities were rated BWR BBB- with a stable outlook, up from CARE BB+ with a stable outlook, while short-term facilities were rated BWR A3, up from CARE A4+. The company manufactured empty hard gelatin and HPMC capsule shells at its Alwar plant in Rajasthan with installed capacity of about 15 billion capsules a year. Consolidated revenue was about Rs 87.7 crore in the year to March 2026, with exports accounting for 39% of sales and one customer contributing more than 10% of revenue. Its bank ratings had stepped down from BBB in FY23 to BB+ by FY26, while total borrowings stood at Rs 55.78 crore against cash of Rs 7.4 lakh.
Powered by Tijori
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Sunil Healthcare do?
Sunil Healthcare Ltd. is a leading manufacturer of Empty Hard Gelatine Capsules (EHGC) in India, with over three decades of experience. They are also involved in producing EHG Capsule Shells and marketing food products.
Who are the competitors of Sunil Healthcare?
Sunil Healthcare major competitors are Eiko Lifesciences, Polychem, Advance Petrochem., AVSL Industries, Mysore PetroChemical, Renol Polychem, Midaas Fashions. Market Cap of Sunil Healthcare is ₹72 Crs. While the median market cap of its peers are ₹74 Crs.
Is Sunil Healthcare financially stable compared to its competitors?
Sunil Healthcare seems to be less financially stable compared to its competitors. Altman Z score of Sunil Healthcare is 1.62 and is ranked 8 out of its 8 competitors.
Does Sunil Healthcare pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Sunil Healthcare latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Sunil Healthcare allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Sunil Healthcare balance sheet?
Sunil Healthcare balance sheet is weak and might have solvency issues
Is the profitablity of Sunil Healthcare improving?
The profit is oscillating. The profit of Sunil Healthcare is ₹3.56 Crs for TTM, ₹4.01 Crs for Mar 2026 and -₹1.42 Crs for Mar 2025.
Is the debt of Sunil Healthcare increasing or decreasing?
The net debt of Sunil Healthcare is decreasing. Latest net debt of Sunil Healthcare is ₹51.19 Crs as of Mar-26. This is less than Mar-25 when it was ₹62.49 Crs.
Is Sunil Healthcare stock expensive?
Sunil Healthcare is not expensive. Latest PE of Sunil Healthcare is 20.19, while 3 year average PE is 35.86. Also latest EV/EBITDA of Sunil Healthcare is 10.11 while 3yr average is 13.34.
Has the share price of Sunil Healthcare grown faster than its competition?
Sunil Healthcare has given better returns compared to its competitors. Sunil Healthcare has grown at ~0.73% over the last 1yrs while peers have grown at a median rate of -8.0%
Is the promoter bullish about Sunil Healthcare?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Sunil Healthcare is 73.53% and last quarter promoter holding is 73.53%.
Are mutual funds buying/selling Sunil Healthcare?
There is Insufficient data to gauge this.